How do I set a price alert for FATE?

To set a FATE price alert on Stock Alarm Pro, navigate to the FATE quote page, select "Set Alert," choose your trigger type (price target, % move, RSI level, MACD, or volume breakout), and set your delivery channel. Stock Alarm Pro supports instant push notifications, SMS, and automated phone call alerts.

Can I get phone call alerts for FATE?

Yes. Stock Alarm Pro provides real-time automated phone call alerts for FATE. Phone call alerts ensure you are immediately awakened or interrupted during critical volatility events, overnight earnings moves, or strict stop-loss levels when silent push notifications might be overlooked.

What types of alerts can I set for Fate Therapeutics Inc?

Stock Alarm Pro supports over 125 trigger types for FATE: price target alerts (above/below target), intraday percentage moves, RSI overbought/oversold levels, 50-day and 200-day moving average crossovers (golden cross / death cross), relative volume (RVOL) spikes, confirmed earnings date releases, and SEC Form-4 insider transaction filings.

How quickly will I be notified about FATE price changes?

FATE alerts are evaluated continuously in real-time against live market telemetry. Notifications are dispatched within sub-second latency via push notifications, SMS, or phone calls as soon as your trigger condition is met across regular, pre-market, and after-hours trading sessions.

Is Stock Alarm Pro free to use for FATE alerts?

Yes, Stock Alarm Pro offers a free tier that includes 3 active price alerts for FATE and other stocks. Full Pro membership is $20/month or $168/year with a 7-day free trial, unlocking unlimited alerts, phone call delivery, SMS, all 125+ technical indicators, institutional screeners, and real-time market telemetry across web, iOS, and Android.

Fate Therapeutics, Inc.(FATE)

$2.29—

WatchlistAsk AI Chart

Fate Therapeutics, Inc.(FATE)

NASDAQAbout this data

$2.29—

WatchlistAsk AI Chart Studio

FATE(FATE)

FATE

10/7/26

Fate Therapeutics (FATE)

Wednesday

4:26 AM

ThesisFate Therapeutics: the risks are mounting — Clinical trial failure risk - iPSC-derived allogeneic cell therapies face unproven efficacy and safety profiles versus…

Revenue Outlook

Metric	FY2025	FY2026E	FY2027E
Revenue	$7M	$6M	$5M
Rev. Growth	-51.2%	-15.7%	-17.3%
EPS	$-1.15	$-1.07	$-1.05
EPS Growth	+29.9%	+7.1%	+1.6%
P/E	—	—	—

★ Analysts see FY2026 revenue reaching $6M — -15.7% growth in a single year.

What Could Go Wrong

01Clinical trial failure risk - iPSC-derived allogeneic cell therapies face unproven efficacy and safety profiles versus established autologous CAR-T. Any serious adverse events or lack of durable responses could invalidate entire platform
02Regulatory pathway uncertainty - FDA has limited precedent for iPSC-derived products, creating risk of unexpected requirements, delays, or rejection
03Manufacturing complexity and scalability - iPSC differentiation and quality control at commercial scale remains unproven, with potential for batch failures or cost overruns
04Reimbursement uncertainty - payers may resist coverage for off-the-shelf cell therapies without clear cost-effectiveness versus existing treatments
05Autologous CAR-T incumbents (GILD's Kite, BMY's Breyanzi) have established efficacy and are improving manufacturing speed, potentially negating FATE's off-the-shelf advantage
06Allogeneic competitors (CRSP, BEAM, ALLO) pursuing alternative approaches (gene editing, base editing) may achieve superior persistence and efficacy
07Large pharma in-house cell therapy programs could leverage greater resources and commercial infrastructure
08Cash burn sustainability - with -$100M operating cash flow and minimal revenue, company faces recurring dilution risk. At current burn rate, existing cash may provide 12-18 months runway, necessitating near-term financing

FY2025 Snapshot

Revenue: $7M
Rev. Growth: -51.2%
Gross Margin: -94.1%
Op. Margin: -2222%
Net Margin: -2051%
Net Income: $-136M
NI Growth: +26.8%
EPS: $-1.15
1Y Return: +89.3%

FATE Chart

My Notes

growth/speculative - Attracts high-risk tolerance investors seeking asymmetric returns from successful clinical development.
High sensitivity through multiple channels: (1) Valuation - biotech DCF models heavily weight distant cash flows…
Watch on earnings: Clinical trial data releases for FT596, FT522, and other lead candidates - objective response rates, duration of response, safety profile, Cash and cash equivalents balance relative to quarterly burn rate - runway calculation, NASDAQ Biotechnology Index (NBI) performance as sector sentiment proxy.

One Sentence Summary:

The bear case: clinical trial failure risk - ipsc-derived allogeneic cell therapies face unproven efficacy and safety profiles versus established autologous car-t.

Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.

Explore More

Stock Comparison

Compare equities side by side

52-Week Highs Breakout

Stocks breaking to new annual highs

52-Week Lows Oversold

S&P 500 oversold value screener

Trending Momentum

Relative strength momentum leaders

Earnings Calendar

Upcoming earnings dates & reports

S&P 500 Screener

Filter and sort all 500 stocks

Strategy Focus List

Continuous multi-factor scoring & catalyst forensics

Market Movers

Today's biggest gainers and losers

Metric

FY2025

FY2026E

FY2027E

P/E

—

What Could Go Wrong

01Clinical trial failure risk - iPSC-derived allogeneic cell therapies face unproven efficacy and safety profiles versus established autologous CAR-T. Any serious adverse events or lack of durable responses could invalidate entire platform

02Regulatory pathway uncertainty - FDA has limited precedent for iPSC-derived products, creating risk of unexpected requirements, delays, or rejection

03Manufacturing complexity and scalability - iPSC differentiation and quality control at commercial scale remains unproven, with potential for batch failures or cost overruns

04Reimbursement uncertainty - payers may resist coverage for off-the-shelf cell therapies without clear cost-effectiveness versus existing treatments

05Autologous CAR-T incumbents (GILD's Kite, BMY's Breyanzi) have established efficacy and are improving manufacturing speed, potentially negating FATE's off-the-shelf advantage

06Allogeneic competitors (CRSP, BEAM, ALLO) pursuing alternative approaches (gene editing, base editing) may achieve superior persistence and efficacy

07Large pharma in-house cell therapy programs could leverage greater resources and commercial infrastructure

08Cash burn sustainability - with -$100M operating cash flow and minimal revenue, company faces recurring dilution risk. At current burn rate, existing cash may provide 12-18 months runway, necessitating near-term financing

My Notes

growth/speculative - Attracts high-risk tolerance investors seeking asymmetric returns from successful clinical development.

High sensitivity through multiple channels: (1) Valuation - biotech DCF models heavily weight distant cash flows…

Watch on earnings: Clinical trial data releases for FT596, FT522, and other lead candidates - objective response rates, duration of response, safety profile, Cash and cash equivalents balance relative to quarterly burn rate - runway calculation, NASDAQ Biotechnology Index (NBI) performance as sector sentiment proxy.